Interleukin-18 in adult-onset still's disease: Treatment target or disease activity indicator?

Internal Medicine

Volumn 51, Issue 4, 2012, Pages 449-

  Nagashima, Takao ^a   Iwamoto, Masahiro ^a   Matsumoto, Kazuko ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adult onset still's disease; Interleukin 18; Interleukin 6; Matrix metalloproteinase 3; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; INTERLEUKIN 18; INTERLEUKIN 6; PREDNISOLONE; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT ONSET STILL DISEASE; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG TARGETING; FERRITIN BLOOD LEVEL; HUMAN; LETTER;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE, MULTIPLE; HUMANS; INTERLEUKIN-18; MALE; STILL'S DISEASE, ADULT-ONSET;

EID: 84857152195     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6678     Document Type: Letter

References (5)

1. Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease. Intern Med 50: 1757-1760, 2011.
2. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 28: 485-487, 2009.
3. Iwamoto M, Onishi S, Yoshio T, Minota S. Serum levels of IL-18 in adult Still's disease during the treatment with tocilizumab. Ann Rheum Dis 68 (Suppl 3): 321, 2009 (abstract).
4. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52: 1794-1803, 2005.
5. Nagashima T, Minota S. Comment on: Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 50: 994-996, 2011.